Haemonetics Corporation (HAE) Q1 2025 Earnings Report

Haemonetics Corporation (HAE) reported its Q1 2025 financial results showcasing a revenue of $336.2 million, with an 8% increase on a reported basis but a decrease in organic growth of 3%. Management highlighted strategic advancements in technology and product integration, particularly in the Plasma and Hospital segments, as critical to navigating current market dynamics impacted by external challenges. The company maintained guidance for growth amidst reinvestment in innovation and market expansion, particularly in response to heightened demand for blood components and plasma therapies. However, challenges persisted in specific customer transitions and supply chain adaptations.